Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association - 1 Jul 2017

Ren Qian, Han Xueyao, Ren Jin, Liu Xinyu, Ji Linong

Abstract excerpt

Sulfonylureas are widely used class of drugs for the treatment of type 2 diabetes (T2DM). Recent research has demonstrated that SLCO1B3 functions as a determinant of the insulinotropic effect of glibenclamide at the tissue level. However, whether this gene can influence the efficacy of glibenclamide in type 2 diabetic patients is not currently well-understood. All of our study subjects were enrolled from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Glyburide

Share to Models, Genetic

Share to Mutation, Missense

Share to Solute Carrier Organic Anion Transporter Family Member 1B3

Share to Treatment Failure

Source

Identifiers

PMID: 28444661
DOI: 10.1055/s-0043-103968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China.PMID 28444661Read ↗

Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.Semantic proximity Read ↗

Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes.Semantic proximity Read ↗

Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c LevelsSemantic proximity Read ↗

Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population.Semantic proximity Read ↗

CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 DiabetesSemantic proximity Read ↗

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Semantic proximity Read ↗

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.Semantic proximity Read ↗

Clinical Study on the Relationship between the SNP rs8192675 (C/C) Site of SLC2A2 Gene and the Hypoglycemic Effect of Metformin in Type 2 Diabetes.Semantic proximity Read ↗

Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patientsSemantic proximity Read ↗

Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics.Semantic proximity Read ↗

The Effect of Genetic Variants of SLC22A2 (rs662301 and rs315978) on the response to Metformin in type 2 Saudi diabetic patients.Semantic proximity Read ↗

The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.